This Review discusses the links between the E3 ubiquitin ligase COP1 and cancer, as shown by mouse models and human tumour data. It describes the evidence for COP1 targeting both oncoproteins and tumour suppressor proteins for degradation, how these apparently contradictory data might be rectified and the therapeutic implications.